News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly New US FDA approval for alirocumab Familial hypercholesterolaemia in China – registry urgently needed OSLER 5-year data in Japanese: evolocumab continues to impress Who is receiving PCSK9 inhibitors in the real world?ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

Events

Posted on 14 November 2016 |

Cardiometabolic Health Congress 2019 (CMHC 2019)
Event start date: 3 May 2019
Pheonix, USA

Asian Pacific Society of Cardiology Congress 2019 (APSC 2019)
Event start date: 22 May 2019
Manila, The Philippines

87th European Atherosclerosis Society
Event start date: 26 May 2019
Maastricht, The Netherlands

British Cardiovascular Society Annual Conference 2019 (BCS 2019)
Event start date: 3 Jun 2019
Manchester, UK

14th Asian Interventional Cardiovascular Therapeutics Congress 2018 (AICT 2018)
Event start date: 4 Jul 2019
Singapore, Singapore

European Society of Cardiology Congress
Event start date: 31 Aug 2019
Paris, France

NLA Clinical Lipid Update
Event start date: 13 Sep 2019
Minneapolis, USA

British Association For Cardiovascular Prevention And Rehabilitation Annual Conference
Event start date: 3 Oct 2019
Nottingham, UK

AHA Scientific Sessions
Event start date: 16 Nov 2019
Philadelphia, USA

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.

Educational Partners and Supporters

Events

Find out more

About PCSK9 Education and Research Forum

Our Partnership and Outreach